Results 91 to 100 of about 5,533 (163)

PLATELET ANTIAGGREGANTS: MECHANISMS OF ACTION AND USE ASOCIED RISKS

Vitae, 2009
Cardiovascular diseases are the main cause of death in the world. Next to efforts to reduce the cardiovascular risk factors, several drugs are resorted to decrease morbimortality associated to these diseases: antihypertensive, antidiabetic, hypolipemiant
Iván F. PALOMO G, Constanza I. TORRES U., Rodrigo E. MOORE-Carrasco., Marcelo A. ALARCÓN L., Patricio J. MARAGAÑO L.   +4 more
doaj  

Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction

, 2000
Howard C. Herrmann, David J. Moliterno, E. Magnus Ohman, Amanda Stebbins, Christopher Bode, Amadeo Betriu, Florian Forycki, Jerry S Miklin, William Bachinsky, A. Michael Lincoff, Robert M. Califf, Eric J. Topol   +11 more
openalex   +1 more source

Platelet CD62 expression and PDGF_AB secretion in patients undergoing PTCA and treatment with abciximab [PDF]

, 2001
Jochen Graff, Daniela Andries, Mathias Elsner, Dagmar Westrup, S. Bassus, Nicole Franz, Ute Klinkhardt, S. Harder   +7 more
openalex   +1 more source

Efficacy, Safety, and Role of Antiplatelet Drugs in the Management of Acute Coronary Syndrome: A Comprehensive Review of Literature. [PDF]

Cureus, 2023
Abubakar M, Raza S, Hassan KM, Javed I, Hassan KM, Farrukh F, Hassan KM, Faraz MA.   +7 more
europepmc   +1 more source

Economic Assessment of Platelet Glycoprotein IIb/IIIa Receptor Blockade With Abciximab and Low-Dose Heparin During Percutaneous Coronary Revascularization

, 2000
A. Michael Lincoff, Daniel B. Mark, James E. Tcheng, Robert M. Califf, Mohan Bala, Keaven M. Anderson, Linda Davidson‐Ray, J. David Knight, Catherine F. Cabot, Eric J. Topol   +9 more
openalex   +1 more source

Rescue use of abciximab improves regional left ventricular function after early incomplete reperfusion in acute myocardial infarction [PDF]

, 2001
Goo‐Yeong Cho, Cheol W. Lee, Myeong‐Ki Hong, Duk‐Hyun Kang, Jae‐Kwan Song, Jae‐Joong Kim, Seong‐Wook Park, Seung‐Jung Park   +7 more
openalex   +1 more source

Los inhibidores de los receptores plaquetarios IIb/IIIa en los síndromes coronarios agudos.

Revista Cubana de Cardiología y Cirugía Cardiovascular, 2012
Los inhibidores de los receptores IIb/IIIa, un nuevo grupo de antiagregantes plaquetarios, son potentes bloqueadores del receptor que media la agregación plaquetaria y de ese modo bloquean la vía final común de la formación del trombo plaquetario.
Fidel Manuel Cáceres Lóriga, Horacio Pérez López   +1 more
doaj  

Pathophysiology and Treatment of the No-Reflow Phenomenon in ST-Segment Elevation Myocardial Infarction: Focus on Low-Dose Fibrinolysis during Primary Percutaneous Intervention. [PDF]

Rev Cardiovasc Med, 2023
Pelliccia F, Niccoli G, Zimarino M, Andò G, Porto I, Calabrò P, De Rosa S, Gragnano F, Piccolo R, Moscarella E, Fabris E, Montone RA, Spaccarotella C, Indolfi C, Sinagra G, Filardi PP, Working Group of Interventional Cardiology of the Italian Society of Cardiology.   +16 more
europepmc   +1 more source

Emergent operation for percutaneous coronary rupture after abciximab administration [PDF]

, 2001
Charles S. Roberts, N.Ruben Bocanegra
openalex   +1 more source

Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization [PDF]

, 2001
Eric J. Topol, David J. Moliterno, Howard C. Herrmann, Eric R. Powers, Cindy L. Grines, David J. Cohen, Eric A. Cohen, Michel E. Bertrand, Franz‐Josef Neumann, Gregg W. Stone, Peter M. DiBattiste, Steven J. Yakubov, Paul DeLucca, Laura A. Demopoulos   +13 more
openalex   +1 more source